What is Airsupra studying for acute asthma?

Airsupra is being studied to see if starting it in the emergency department helps reduce the chance of asthma worsening or returning within three months. This study compares Airsupra to usual care in adults with acute asthma and is sponsored by Massachusetts General Hospital. It aims to improve asthma management after emergency visits.

Who may be eligible for this acute asthma clinical trial?

Adults aged 18 to 54 with acute asthma who are discharged from the emergency department on corticosteroids may be eligible. Participants must speak English or Spanish and be able to use the Airsupra inhaler correctly. People with COPD or recent steroid use may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this acute asthma clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel needs.

Actively Recruiting

Phase 4

Age: 18Years - 54Years

All Genders

ID07166939

A Phase 4, Multicenter, Cluster Randomized, Open-label Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes

Led by Massachusetts General Hospital · Updated on 2026-04-17

1860

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the effect of starting Airsupra inhaler treatment in emergency departments ED on reducing acute asthma recurrence and other related outcomes over three months. The study focuses on adults aged 18 to 54 who visit the ED for asthma exacerbations and are discharged with a short course of systemic corticosteroids. This trial is a cluster randomized, open-label study comparing Airsupra use to usual care across multiple centers. Participants will be assigned by site to either receive usual care or Airsupra as their rescue inhaler along with corticosteroids. Airsupra dosing is as needed, with up to six doses per day. The study will run for about four to five months of enrollment per site, with follow-up assessments conducted at approximately 3, 6, and 12 weeks after the ED discharge to monitor asthma control, relapse, and recurrence. During the study, patients will complete interviews and chart reviews in the ED, and follow-up will include telephone or text contact to assess their clinical status and medication use. Medical records from before and after enrollment will be reviewed to identify asthma exacerbations. The main outcome is asthma recurrence within three months, with asthma control and early relapse also measured. Participants data will be securely managed throughout the study period, which extends up to 12 weeks post-ED visit.

CONDITIONS

Brief Title

45th Multicenter Airway Research Collaboration

Who Can Participate

Age: 18Years - 54Years

All Genders

Eligibility Criteria

You may qualify if you...

Acute asthma diagnosis
Age between 18.0 and 54.9 years
English and/or Spanish speaking
Decision by emergency department attending to discharge patient to home on a short course of systemic corticosteroids
(Intervention group only) Willingness to use Airsupra as rescue inhaler for the next 3 months
Demonstration of acceptable metered dose inhaler administration technique
Provision of informed consent before any study procedures

You will not qualify if you...

Involvement in planning or conduct of the study
Previous enrollment in this study
Prior diagnosis of COPD, chronic bronchitis, or emphysema
Use of systemic corticosteroids in the past 2 weeks
Participation in another clinical study with an investigational product during the past 4 weeks or 3 months after enrollment
Concurrent pneumonia
Clinically significant cardiovascular disease or cancer
Known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any product excipients
For women: currently pregnant or breastfeeding
For sexually active women of child-bearing age: not using or planning to use adequate contraception over the study period
Lack of a working cell phone and working email address
Expected unavailability for follow-up at approximately 3, 6, and 12 weeks
Inability to provide an alternate contact with a working cell phone and email address

Research Team

Carlos A Camargo, MD, DrPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here